Skip to main content

Kinarus secures capital commitment of 57 million Swiss francs

| News

Kinarus secures capital commitment of 57 million Swiss francs

13.09.2021

The biopharmaceutical company Kinarus has signed a capital commitment of up to 57 million Swiss francs with the investment group GEM. This should support the phase II trial for Kinarus’ clinical drug candidate to treat a retinal disease.

Kinarus can fund the phase 2 trial for its clinical drug candidate KIN001 for the treatment of wet macular degeneration with up to 57 million Swiss francs. The biopharmaceutical company headquartered at the Technologiepark Basel has received a corresponding capital commitment from the investment group Global Emerging Markets (GEM). It has a term of 36 months. According to a press release from the company, Kinarus can draw the funds at any time and “within certain limits” during this period. The self-styled “alternative” investment group is based in Luxembourg. It has branches in New York, Paris and the Bahamas.

First, the reverse takeover by Perfect Holding based in Lausanne in the canton of Vaud announced in mid-August is planned to be concluded. Since the sale of its subsidiary Oxygen Aviation in April 2020, Perfect Holding is now just a shell but it is listed on the SIX Swiss Exchange. A reverse takeover can make private companies into listed companies without having to undergo flotation. According to the press release, Kinarus is expected to be listed this year subject to approval of the shareholders and conclusion of the series B financing round.

According to the CEO of Kinarus, Alexander Bausch, this additional capital will help to “broaden the clinical phase 2 portfolio of KIN001 in additional indications of high medical need.” The company further states that it has several patents covering the use of KIN001 in numerous indications. In April, Kinarus started the phase 2 trial KINETIC with KIN001, in which patients hospitalized with COVID-19 are now being treated with KIN001.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.